Dixon Hubard Feinour & Brown’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $4.79M | Sell |
62,172
-2,725
| -4% | -$208K | 0.57% | 57 |
|
|
2022
Q1 | $4.74M | Buy |
64,897
+3,785
| +6% | +$254K | 0.47% | 62 |
|
|
2021
Q4 | $3.81M | Buy |
61,112
+8,010
| +15% | +$470K | 0.37% | 74 |
|
|
2021
Q3 | $3.14M | Buy |
53,102
+16
| +0% | +$1.05K | 0.67% | 39 |
|
|
2021
Q2 | $3.55M | Sell |
53,086
-58,084
| -52% | -$3.79M | 0.74% | 36 |
|
|
2021
Q1 | $6.86M | Buy |
111,170
+55,106
| +98% | +$3.43M | 0.85% | 33 |
|
|
2020
Q4 | $3.38M | Hold |
56,064
| – | – | 0.87% | 31 |
|
|
2020
Q3 | $3.38M | Sell |
56,064
-225
| -0.4% | -$13.5K | 0.87% | 31 |
|
|
2020
Q2 | $3.35M | Buy |
56,289
+795
| +1% | +$47.6K | 0.87% | 32 |
|
|
2020
Q1 | $3.09M | Sell |
55,494
-2,941
| -5% | -$180K | 1.05% | 33 |
|
|
2019
Q4 | $3.75M | Sell |
58,435
-110
| -0.2% | -$6.3K | 0.97% | 34 |
|
|
2019
Q3 | $2.97M | Buy |
58,545
+100
| +0.2% | +$4.7K | 0.82% | 36 |
|
|
2019
Q2 | $2.65M | Sell |
58,445
-1,566
| -3% | -$72.9K | 0.75% | 37 |
|
|
2019
Q1 | $2.86M | Sell |
60,011
-635
| -1% | -$31.6K | 0.86% | 34 |
|
|
2018
Q4 | $3.15M | Sell |
60,646
-1,495
| -2% | -$80.3K | 1.17% | 28 |
|
|
2018
Q3 | $3.86M | Sell |
62,141
-1,425
| -2% | -$84.6K | 1.07% | 31 |
|
|
2018
Q2 | $3.52M | Sell |
63,566
-857
| -1% | -$46.3K | 1.02% | 32 |
|
|
2018
Q1 | $4.08M | Buy |
64,423
+2,690
| +4% | +$173K | 1.14% | 29 |
|
|
2017
Q4 | $3.78M | Buy |
61,733
+711
| +1% | +$44.5K | 1.02% | 32 |
|
|
2017
Q3 | $3.89M | Sell |
61,022
-1,324
| -2% | -$77.3K | 1.12% | 30 |
|
|
2017
Q2 | $3.47M | Sell |
62,346
-1,000
| -2% | -$54.4K | 1% | 31 |
|
|
2017
Q1 | $3.44M | Sell |
63,346
-1,400
| -2% | -$76.8K | 1.03% | 30 |
|
|
2016
Q4 | $3.78M | Sell |
64,746
-8,475
| -12% | -$463K | 1.2% | 29 |
|
|
2016
Q3 | $3.95M | Buy |
73,221
+1,405
| +2% | +$90.3K | 1.22% | 29 |
|
|
2016
Q2 | $5.28M | Sell |
71,816
-1,075
| -1% | -$76K | 1.69% | 19 |
|
|
2016
Q1 | $5.26M | Sell |
72,891
-2,055
| -3% | -$130K | 1.72% | 19 |
|
|
2015
Q4 | $5.16M | Sell |
74,946
-837
| -1% | -$55.3K | 1.64% | 20 |
|
|
2015
Q3 | $4.49M | Sell |
75,783
-308
| -0.4% | -$19.5K | 1.65% | 20 |
|
|
2015
Q2 | $5.06M | Sell |
76,091
-358
| -0.5% | -$23.6K | 1.56% | 23 |
|
|
2015
Q1 | $4.93M | Buy |
76,449
+1,451
| +2% | +$90.8K | 1.46% | 23 |
|
|
2014
Q4 | $4.43M | Sell |
74,998
-2,748
| -4% | -$155K | 1.38% | 28 |
|
|
2014
Q3 | $3.98M | Sell |
77,746
-1,044
| -1% | -$52.1K | 1.3% | 31 |
|
|
2014
Q2 | $3.82M | Sell |
78,790
-9,160
| -10% | -$451K | 1.25% | 32 |
|
|
2014
Q1 | $4.57M | Sell |
87,950
-843
| -0.9% | -$44.9K | 1.58% | 19 |
|
|
2013
Q4 | $4.72M | Sell |
88,793
-2,603
| -3% | -$133K | 1.74% | 17 |
|
|
2013
Q3 | $4.23M | Sell |
91,396
-5,815
| -6% | -$255K | 1.79% | 17 |
|
|
2013
Q2 | $4.34M | Buy |
+97,211
| New | +$4.22M | 1.94% | 15 |
|
Other funds holding BMY
Dixon Hubard Feinour & Brown's BMY Position: Q2 2022 in Review
Dixon Hubard Feinour & Brown reduced its Bristol-Myers Squibb (BMY) stake by 4.2% in Q2 2022, selling an estimated $208K and leaving 62,172 shares worth $4.79M. The position accounts for 0.57% of the portfolio, ranked #57.
Dixon Hubard Feinour & Brown first reported a position in BMY in Q2 2013 and has held it in 37 quarters since. The position peaked at $6.86M in Q1 2021. 2,537 funds tracked by Wall St. Rank hold BMY as of Q2 2022.
- Dixon Hubard Feinour & Brown held 62,172 shares of Bristol-Myers Squibb worth $4.79M as of Q2 2022.
- Dixon Hubard Feinour & Brown sold 2,725 Bristol-Myers Squibb shares in Q2 2022, an estimated $208K.
- Bristol-Myers Squibb made up 0.57% of Dixon Hubard Feinour & Brown's portfolio in Q2 2022, its #57 holding.
- Dixon Hubard Feinour & Brown first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 37 quarters since.
- Dixon Hubard Feinour & Brown's Bristol-Myers Squibb position peaked at $6.86M in Q1 2021.
- 2,537 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2022.
Based on Dixon Hubard Feinour & Brown's 13F filing for Q2 2022, filed 22 Jul 2022.